“Phase II Study of Irinotecan in Combination with Capecitabine on a 3-Weekly Schedule as First-Line Chemotherapy for Patients with Metastatic or Locally Advanced Colorectal Cancer”, J. Anal. Oncol., vol. 2, no. 3, pp.  151–159, Aug. 2013, doi: 10.6000/1927-7229.2013.02.03.4.